What is the role of direct thrombin inhibitors in deep venous thrombosis (DVT) prophylaxis for patients undergoing orthopedic surgery?

Updated: Jan 28, 2021
  • Author: David A Forsh, MD; Chief Editor: Vinod K Panchbhavi, MD, FACS, FAOA, FABOS, FAAOS  more...
  • Print


In November 2015, the FDA approved dabigatran for prophylaxis of DVT and PE after hip replacement surgery. Approval was based on the RE-NOVATE and RE-NOVATE II trials. [53, 54] Dabigatran was found to have similar effectiveness and safety in preventing VTE following hip arthroplasty as compared with enoxaparin

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!